Biologic therapy for lymphoma
作者:
Maurizio Bendandi,
Dan Longo,
期刊:
Current Opinion in Oncology
(OVID Available online 1999)
卷期:
Volume 11,
issue 5
页码: 343-343
ISSN:1040-8746
年代: 1999
出版商: OVID
数据来源: OVID
摘要:
Biologic approaches to lymphoma treatment are now a practical reality rather than a vaguely perceived hope for the future. Interferon alfa seems to have been established as a life-extending therapy for selected patients with follicular lymphoma. Humanized anti-CD20 monoclonal antibody (rituximab) has an authentic 50% response rate in patients with follicular lymphoma, frequently works when given a second time, and is demonstrating what seems to be synergistic activity when combined with chemotherapy. Radioimmunoconjugates using iodine-131 and yttrium-90 as payload are producing responses in refractory and aggressive lymphomas. Vaccines and adoptive cellular therapies are also showing promising results in early phase clinical testing.
返 回